We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amarin (AMRN) Stock Moves -0.49%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Amarin (AMRN - Free Report) closed at $16.15, marking a -0.49% move from the previous day. This move was narrower than the S&P 500's daily loss of 0.94%. Elsewhere, the Dow lost 0.87%, while the tech-heavy Nasdaq lost 1.18%.
Coming into today, shares of the biopharmaceutical company had gained 7.98% in the past month. In that same time, the Medical sector gained 6.01%, while the S&P 500 gained 8.01%.
AMRN will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$0.05, up 37.5% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $74.45 million, up 38.2% from the year-ago period.
Any recent changes to analyst estimates for AMRN should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 29.41% higher. AMRN is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 58, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amarin (AMRN) Stock Moves -0.49%: What You Should Know
In the latest trading session, Amarin (AMRN - Free Report) closed at $16.15, marking a -0.49% move from the previous day. This move was narrower than the S&P 500's daily loss of 0.94%. Elsewhere, the Dow lost 0.87%, while the tech-heavy Nasdaq lost 1.18%.
Coming into today, shares of the biopharmaceutical company had gained 7.98% in the past month. In that same time, the Medical sector gained 6.01%, while the S&P 500 gained 8.01%.
AMRN will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$0.05, up 37.5% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $74.45 million, up 38.2% from the year-ago period.
Any recent changes to analyst estimates for AMRN should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 29.41% higher. AMRN is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 58, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.